Abstract
Clinical trials of BNCT for the treatment of glioblastoma and melanoma using 4-dihydroxyborylphenylalanine (BPA) as the boron compound have proven to be efficacious. In 1992, the 11C l led 1-amino-cyclobutanecarboxylic acid (ACBC) for diagnosing brain tumors by PET imaging has been evidenced to be more accurate than 18F-FDG, being with tumor-to-normal tissue uptake ratio up to 10:1. In this study, 1-amino-3-(4-boronophenyl) cyclobutane carboxylic acid, a BPA analogue, with a moiety of ACBC structure, was synthesized and developed as a BNCT drug for treatment of brain and liver tumors.The synthetic process involves 7 steps. The optimal condition for each step has been closely investigated. The key synthetic procedure is pertinent to the initial two steps. The reaction may become incomplete and lead to a low product-yield if existence of moisture. In addition, the last two steps involve Bucherer-Strecker reaction; the reactivity is inherently limited, resulting in a low product-yield. The final product, 1-amino-3-(4-boronophenyl) cyclobutane carboxylic acid was purified via a silica gel column chromatography. The intermediate and final products were identified by 1H-NMR and 13C-NMR. The efficacy of the boron-contained amino acid for treatment of either brain tumor or liver tumor is being assessed by animal tests at National Chung Hsing University and Taipei Veterans General Hospital. It is anticipated that this boronated amino acid compound be efficacious as a BNCT agent in the future.